Background: The aim of study was to explore the prevalence and clinical characteristics of constipation in Chinese inpatients with schizophrenia and analyze its risk factors. Methods: 806 schizophrenic patients in Shanghai were recruited to analyze the prevalence of constipation and the clinical characteristics of schizophrenic patients. According to whether the patients had constipation, they were divided into constipation group and normal group. The living conditions of the two groups were compared, and the risk factors of constipation were analyzed. Finally, the ROC curve was used to determine the predictive efficacy of the related factors on constipation, and the utilization of the risk factors Logistic regression analysis was used to determine the important factors of constipation. Results: The prevalence of constipation in Chinese schizophrenic patients was higher than that in the general population. The prevalence of mild constipation was 32.5% in 806 schizophrenic patients, and the prevalence of severe constipation was 20.9%. There was also gender difference in the prevalence of constipation in schizophrenic patients, among which the prevalence of female constipation was 17.6%, and that of male constipation was 9.9%. The dietary habits of patients also had a significant impact on the prevalence of constipation (P=0.001). Conclusion: The risk of constipation in female patients with schizophrenia is significantly higher than that in male patients. The incidence of constipation is related to gender, age, education level, negative symptoms, PANSS total score, smoking, exercise and drinking water. Gender, education level and daily smoking are important predictors of constipation.

Yan Kong, Jianjun Hu, Xirong Sun, Haiying Min, Ling Wang, JieYuan, Jiechun Zhang, Xiangyang Zhang. Original article of prevalence, risk factors and clinical characteristics of constipation in Chinese patients with schizophrenia. Frontiers in Medical Science Research (2022) Vol. 4, Issue 15: 55-64. https://doi.org/10.25236/FMSR.2022.041509.

[1] Sharma A, Rao S. Constipation: Pathophysiology and Current Therapeutic Approaches. Handbook of Experimental Pharmacology, 2017, 239: 59-74.

[2] Kanaki AA, Singanal S. Efficacy and safety of prucalopride in the treatment of chronic constipation. International Journal of Basic & Clinical Pharmacology, 2018, 7(5):998.

[3] Jiang Y, Tang Y, Lin L. Clinical Characteristics of Different Primary Constipation Subtypes in a Chinese Population. Journal of Clinical Gastroenterology, 2019, 54(7):1.

[4] Alonso Y, Alba Valiente-Pallejà, Verge B, et al. High frequency of clinical conditions commonly associated with mitochondrial disorders in schizophrenia. Acta Neuropsychiatrica, 2020, 32(5):1-16.

[5] Bentsen H, Cuenod M, Do KQ. Glutathione related factors in two biotypes of schizophrenia. Schizophrenia Bulletin, 2019, 45(Supplement_2):S309-S309.

[6] Lin CH, Chan HY, Hsu CC, et al. Factors associated with laxative use in schizophrenia patients treated with second-generation antipsychotics. European Neuropsychopharmacology, 2021, 43:139-146.

[7] Yamada E, Namiki Y, Takano Y, et al. Clinical factors associated with the symptoms of constipation in patients with diabetes mellitus: A multicenter study. Journal of Gastroenterology & Hepatology, 2018, 33(4):863-868.

[8] Oddur, Ingimarsson, James H, et al. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nordic journal of psychiatry, 2018,72(7):497-500.

[9] Chen HK, Hsieh CJ. Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. Schizophrenia Research, 2017:396-409.

[10] Chih-Chieh Chang, Hsing-Kang Chen. The Prevalence of Constipation and Its Risk Factors in Patients with Schizophrenia. Taiwanese Journal of Psychiatry (Taipei) 2021; 35: 95-98

[11] Lu YS, Chen YC, Kuo SH, et al.: Prevalence of antipsychotic drugs related to constipation in patients with schizophrenia. Taiwan J Psychiatry 2016; 30: 294-9.

[12] Shirazi A, Stubbs B, Gomez L, et al.: Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci 2016; 17: 863.

[13] Kalinowska S, Trześniowska-Drukała, Beata, Safranow K, et al. Association between thyroid function and metabolic syndrome in male and female schizophrenia patients. Psychiatry Research, 2019, 274: 167-175.

[14] Adamowicz K, Kucharska-Mazur J. Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients. Journal of Clinical Medicine, 2020, 9(2):537.

[15] Peng Men, Zhanmiao Yi, Chaoyun Li et al. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC psychiatry, 2018,18(1):286.

[16] Every-Palmer S, Ellis PM, Nowitz M, et al. The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study. CNS Drugs, 2017, 31(1):75-85.

[17] Pristed SG, Correll CU, Nielsen J. Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. Psychiatry Res, 2017:198-203.

[18] Schwasinger-Schmidt, Macaluso TE, Other Antidepressants. Handbook of experimental pharmacology, 2019, 250:325-355. 

[19] Attard A, Iles A, Attard S, et al. Clozapine: why wait to start a laxative?. BJP sych Advances, 2019, 25(6):377-386.

[20] Lin CC, Hung YY, Tsai M C , et al. Increased serum brain-derived neurotrophic factor in male schizophrenic patients with metabolic syndrome. Medicine, 2017, 96(22):e7089.

[21] Petkari, Eleni & Mayoral., Fermín & Moreno-Küstner, Berta. Gender Matters in Schizophrenia-spectrum Disorders: Results from A Healthcare Users Epidemiological Study in Malaga, Spain. Comprehensive Psychiatry. 2017, 72. 136-143. 

[22] Silva NLD, Galhenage J, Dayabandara M, et al. Sheehan Syndrome Presenting with Psychotic Manifestations Mimicking Schizophrenia in a Young Female: A Case Report and Review of the Literature. Case Reports in Endocrinology, 2020, 2020(5):1-6.

[23] Viswam S K, Maheswari E, Singh H, et al. Adverse drug reactions due to atypical antipsychotics in the absence of other centrally acting drugs among patients with mental illness. Archives of Pharmacy Practice, 2019, 10(2):105-109.

[24] Yen C C, Tze-Chun T, Tzu-Ting C, et al. Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan. Neuropsychiatric Disease & Treatment, 2018, 14:725-732.

[25] Hideaki K, Masanori T, Shinpei K, et al. Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study. Neuropsychiatric Disease & Treatment, 2018, 14:265-272.

[26] Susanna Every-Palmer, Pete M Ellis. Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison with International Drug Safety Advice. CNS Drugs, 2017, 31:699-709.

[27] Biagi E, Capuzzi E, Colmegna F, et al. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in Therapy, 2017, 34(5):1036–1048.

[28] Wang J, Li C, Zhu XM, et al. Association between schizophrenia and violence among Chinese female offenders. Scientific Reports, 2017, 7(1):818.

[29] Mao Sheng, Ran WenJun, et al. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. British Journal of Psychiatry, 2018, 206(4):283-288.

[30] Sommer I E, Tiihonen J, Mourik AV, et al. The clinical course of schizophrenia in women and men—a nation-wide cohort stud. NPJ Schizophrenia, 2020, 6(1):12.

[31] Hui Wen, Yenju Huang, et al. Nursing Experience with Reconstructing Self-Control Using Rational-Emotive Behavior Therapy on a Patient with Schizophrenia and Obsessive-Compulsive Symptoms. Hu li za zhi The journal of nursing, 2018, 65(5):112-119.

[32] Li X H, An F R, Ungvari G S, et al. Prevalence of smoking in patients with bipolar disorder, major depressive disorder and schizophrenia and their relationships with quality of life. Rep, 2017, 7(1):8430.

[33] Mak Y W, Chiang VCL, Loke A Y. Experiences of Tobacco Use among Chinese Individuals with Schizophrenia in Community-Based Residential Settings: A Qualitative Study. International Journal of Environmental Research and Public Health, 2020, 17(1):321.

[34] Tongu, Utku, Ylmaz, et al. Relationship of functional constipation and anal-retentive behavior features. Turkish journal of surgery, 2018:1-5.

[35] Aocn R J W, R. Managing Constipation in Adults with Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8(2):149-161.

[36] Iqbal E , Govind R , Romero A , et al. The side effect profile of Clozapine in real world data of three large mental health hospitals. PLOS ONE, 2020, 15(12):1-20.

[37] Chougule A , Praharaj S K , Bhat S M , et al. Prevalence and Factors Associated With Clozapine-Related Constipation: An Observational Study. J Clin Psychopharmacol, 2018, 38(1):42-46.

[38] Sayed T , Dalia K , Walid A B , et al. Effects of a proposed physical activity and diet control to manage constipation in middle-aged obese women. Diabetes Metab Syndr Obes, 2017, 10:513-519.

[39] Tomaka J , Karaku?A-Juchnowicz H , Morylowska-Topolska J , et al. Review paper. Gluten-related disorders and schizophrenia - potential linking mechanisms, diagnostic and therapeutic challenge[J]. Current Problems of Psychiatry, 2017, 18(1):9-24.

[40] Andreoli C S , Ribeiro-Vieira S A , Fonsca P C D A , et al. Markers of healthy eating habits, water intake, and constipation in children between 4 and 7 years of age. Revista de Nutrio, 2018, 31(4):363-372.

[41] Sori T , Mavar M , Rumbak I . The Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Metabolic Syndrome in Hospitalized Schizophrenic Patients: A Randomized Controlled Trial. Nutrients, 2019, 11(12):2950.

[42] Wilson P B . Associations between physical activity and constipation in adult Americans: Results from the National Health and Nutrition Examination Survey. Neurogastroenterology and Motility, 2020(1):e13789.

[43] Gao R, Tao Y, Zhou C, Li J, Wang X, Chen L, Li F, Guo L. Exercise therapy in patients with constipation: a systematic review and meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2019 ;54(2):169-177. 

[44] Song BK, Kim YS, Kim HS, Oh JW, Lee O, Kim JS. Combined exercise improves gastrointestinal motility in psychiatric in patients. World J Clin Cases. 2018;6(8):207-213.